Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas To Jointly Develop And Market FD Drug With Zeria

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma and Zeria Pharmaceutical, both based in Tokyo, will co-develop and co-market functional dyspepsia agent Z-338/YM443. Based on the agreement, Zeria will obtain marketing approval in Japan, and both companies will co-market the product under the single brand name. Discovered by Zeria, Z-338/YM443 inhibits peripheral acetylcholinesterase activities, resulting in improvement of delayed gastric emptying, a symptom of FD. Astellas also has obtained exclusive development and marketing rights in North America for Z-338/YM443 and a Phase II trial is underway. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067885

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel